Back to News
Market Impact: 0.3
AbbVie, Genmab's Epcoritamab Plus R-CHOP Improves PFS In DLBCL
Source: Nasdaq
Healthcare & Biotech
AbbVie and Genmab reported positive topline results from the Phase 3 EPCORE DLBCL-2 trial evaluating epcoritamab plus R-CHOP in patients with newly diagnosed diffuse large B-cell lymphoma. The report provided no efficacy figures or further trial details.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.35
Ticker Sentiment
ABBV0.70
GMAB0.70
More News
- European stocks rise 1% as French debt calms and ECB’s Lane tempers hawks
- Stock Movers: Genmab, Sabadell, Vend (Podcast)
- Genmab: Epkinly Shines In Phase 3 DLBCL Trial
- Why is Telix Pharmaceuticals stock rallying today?
- Why is Natera stock sliding today?
- ArriVent BioPharma Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into ArriVent BioPharma (AVBP)